medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2015, Number 4

<< Back Next >>

Ann Hepatol 2015; 14 (4)

Insights in non-alcoholic fatty liver disease pathophysiology with lipidomic analyses

Almeda-Valdes P, Altamirano-Barrera A, Méndez-Sánchez N

Language: English
References: 12
Page: 567-569
PDF size: 64.33 Kb.


Text Extraction

Article commented: Anjani K, Lhomme M, Sokolovska N, Poitou C, Aron-Wisnewsky J, Bouillot JL, Lesnik P, et al. Circulating phospholipid profiling identifies portal contribution to NASH signature in obesity. J Hepatol 2015; 62: 905-12.
Comment:
Non-alcoholic fatty liver disease (NAFLD) has a worldwide prevalence of around 20 to 30% and has been associated to increased liver-related mortality and risk for cardiovascular disease.


REFERENCES

  1. Corey KE, Misdraji J, Gelrud L, Zheng H, Chung RT, Krauss RM. Nonalcoholic steatohepatitis is associated with an atherogenic lipoprotein subfraction profile. Lipids Health Dis 2014; 13: 100.

  2. Almeda-Valdes P, Aguilar-Olivos N, Uribe M, Mendez- Sanchez N. Common features of the metabolic syndrome and nonalcoholic fatty liver disease. Rev Recent Clin Trials 2014; 9: 148-58.

  3. Clark JM, Diehl AM. Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis. JAMA 2003; 289: 3000-4.

  4. Berlanga A, Guiu-Jurado E, Porras JA, Auguet T. Molecular pathways in non-alcoholic fatty liver disease. Clin Exp Gastroenterol 2014; 7: 221-39.

  5. Gorden DL, Ivanova PT, Myers DS, McIntyre JO, VanSaun MN, Wright JK, Matrisian LM, et al. Increased diacylglycerols characterize hepatic lipid changes in progression of human nonalcoholic fatty liver disease; comparison to a murine model. PLoS One 2011; 6: e22775.

  6. Beyoglu D, Idle JR. The metabolomic window into hepatobiliary disease. J Hepatol 2013; 59: 842-58.

  7. Garcia-Ruiz C, Mato JM, Vance D, Kaplowitz N, Fernández- Checa JC. Acid sphingomyelinase-ceramide system in steatohepatitis: a novel target regulating multiple pathways. J Hepatol 2015; 62: 219-33.

  8. Anjani K, Lhomme M, Sokolovska N, Poitou C, Aron-Wisnewsky J, Bouillot JL, Lesnik P, et al. Circulating phospholipid profiling identifies portal contribution to NASH signature in obesity. J Hepatol 2015; 62: 905-12.

  9. Larter CZ, Yeh MM, Haigh WG, Williams J, Brown S, Bell-Anderson KS, Lee SP, et al. Hepatic free fatty acids accumulate in experimental steatohepatitis: role of adaptive pathways. J Hepatol 2008; 48: 638-47.

  10. Day CP, James OF. Steatohepatitis: a tale of two “hits”? Gastroenterology 1998; 114: 842-5.

  11. Li Z, Agellon LB, Allen TM, Umeda M, Jewell L, Mason A, Vance DE. The ratio of phosphatidylcholine to phosphatidylethanolamine influences membrane integrity and steatohepatitis. Cell Metab 2006; 3: 321-31.

  12. Aron-Wisnewsky J, Gaborit B, Dutour A, Clement K. Gut microbiota and non-alcoholic fatty liver disease: new insights. Clin Microbiol Infect 2013; 19: 338-48.




2020     |     www.medigraphic.com